Showing results (251-260 of 676) with videos related to
Sort By:
Pageof 68
Clinical Advances in Hematology & Oncology : H&O|November 17, 2020
Workup of anemia in cancerSidharth Anand, Aaron Burkenroad, John GlaspyClinical Advances in Hematology & Oncology : H&O|November 17, 2020
PARP inhibition in recurrent ovarian cancerKathleen N Moore, Bhavana Pothuri, Bradley Monk, et al.Clinical Advances in Hematology & Oncology : H&O|April 10, 2015
New and emerging therapeutic options for the management of chemotherapy-induced nausea and vomitingLee S Schwartzberg, Hope S Rugo, Matti S AaproClinical Advances in Hematology & Oncology : H&O|March 17, 2015
Long-term toxicity of chemotherapy and radiotherapy in lymphoma survivors: optimizing treatment for individual patientsDavid C HodgsonClinical Advances in Hematology & Oncology : H&O|March 17, 2015
Advances in the diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphomaNader Kim El-Mallawany, Mitchell S CairoClinical Advances in Hematology & Oncology : H&O|May 5, 2023
Novel approaches to the treatment of multiple myelomaKathryn T Maples, Sara A Scott, Sagar LonialClinical Advances in Hematology & Oncology : H&O|July 29, 2020
The Mechanism of Action of Regorafenib in Colorectal Cancer: A Guide for the Community PhysicianAxel Grothey, Gerald Prager, Takayuki YoshinoClinical Advances in Hematology & Oncology : H&O|April 12, 2021
Clinical actionability of measurable residual disease (MRD) assessment in the management of patients with hematologic malignancies: a case-based monographJeffrey Wolf, Rafael Fonseca, Lori MufflyClinical Advances in Hematology & Oncology : H&O|April 12, 2021
A new strategy for uncontrollable bleeding after treatment with rivaroxaban or apixabanCraig M Kessler, Joshua N GoldsteinClinical Advances in Hematology & Oncology : H&O|April 12, 2021
Optimizing the treatment sequence from second-line to third-line therapy in patients with metastatic colorectal cancerAxel Grothey, Tanios S Bekaii-Saab, Takayuki Yoshino, et al.Pageof 68